Arbutus Biopharma Corporation

NASDAQ:ABUS

Biotechnology

Healthcare
$4.11 +1.13%

+$0.05 today

Market cap
$630.03M
Beta
0.63
P/E (TTM)
5.4
EPS (TTM)
$0.83
52W Low $3.04High $5.10

Volume 2.90M

Average 1.76M

ABUS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Arbutus Biopharma CorporationNASDAQ: ABUS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 100.0%

Gross margin was 100.0% in Q1 FY2026, up 507.9 pp from a year earlier. On a trailing-twelve-month basis it was 100.0%, up 277.5 pp year over year. Over 3 fiscal years it narrowed by 2.6 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.0%+1.0 pp QoQ
Last fiscal yearDec 2025
97.4%-2.6 pp YoY
LTMMar 2026
100.0%+277.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+507.9 pp——
1 year-2.6 pp——
3 years-2.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
97.4%
Year-over-year change
-2.6pp

Gross Margin vs competitors

How ABUS compares with its peers on the latest reported figures

  • ABUS's LTM Mar 2026 gross margin of 100.0% is the 2nd highest of the 7 companies compared; the peer median is 89.0%.
  • Its year-over-year change of +277.5 pp is the 2nd highest of 6, against a peer median of -0.4 pp.
  • Over three fiscal years its change of -2.6 pp compares with a peer median of +4.8 pp.
ABUS Competitors Peer median
Gross Margin for ABUS and competitors
Company Period LTM level YoY 3-year change
VIRVir Biotechnology, Inc.LTM Mar 2026275.2% +2604.6 pp+21.4 pp
ABUSArbutus Biopharma CorporationLTM Mar 2026100.0% +277.5 pp-2.6 pp
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 202699.6% -0.4 pp+4.8 pp
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202698.3% -1.7 pp-7.0 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202679.7% -3.9 pp-2.0 pp
ASMBAssembly Biosciences, Inc.LTM Mar 202677.2% +110.0 pp—
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
BNTCBenitec Biopharma Inc.FY2025— ——
Peer median (excluding ABUS) 89.0%-0.4 pp+4.8 pp

Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.99M39.02M18.14M6.17M14.08M
Cost of Revenue0000363K
Gross Profit10.99M39.02M18.14M6.17M13.72M
Gross Margin100.0%100.0%100.0%100.0%97.4%
Research & Development65.5M84.41M73.7M54.04M25.24M
Selling, General & Admin17.14M17.83M22.48M22.11M15.89M
Operating Expenses84.51M104.48M96.24M82.49M40.77M
Depreciation & Amortization1.75M1.43M1.4M1.38M363K
EBITDA(71.64M)(61.86M)(70.99M)(68.4M)(33.04M)
EBITDA Margin-652.0%-158.5%-391.3%-1108.5%-234.6%
Operating Income(73.52M)(65.46M)(78.1M)(76.32M)(27.05M)
Operating Margin-669.1%-167.8%-430.5%-1236.7%-192.1%
Interest Income127K2.19M5.69M6.59M4.07M
Interest Expense2.86M1.73M459K137K97K
Other Income / Expenses(2.73M)444K5.25M6.4M(6.45M)
Income Before Tax(76.25M)(65.01M)(72.85M)(69.92M)(33.5M)
Pre-Tax Margin-693.9%-166.6%-401.6%-1133.0%-237.9%
Income Tax Expense04.44M000
Net Income(76.25M)(69.46M)(72.85M)(69.92M)(33.5M)
Net Margin-693.9%-178.0%-401.6%-1133.0%-237.9%
EPS (Basic)(0.73)(0.46)(0.44)(0.38)(0.17)
EPS (Diluted)(0.73)(0.46)(0.44)(0.38)(0.17)
Weighted Avg Shares106.24M150.94M165.96M185.61M191.6M
Weighted Avg Shares (Diluted)106.24M150.94M165.96M185.61M191.6M

Arbutus Biopharma Corporation

NASDAQ:ABUS

Intrinsic Alpha fair value

Locked

Current Price

$4.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.